What prior Ebola-related context did NanoViricides reference in this filing?

The company noted remdesivir’s prior Ebola clinical trial, where two antibody therapies outperformed it and were approved for EBOV Zaire. Remdesivir’s safety and tolerability data, along with earlier animal model activity, were cited as the basis for its later COVID-19 clinical development and approval.

NanoViricides (NNVC) outlines NV-387 antiviral and remdesivir combo at AGP event

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

NanoViricides, Inc. reported that its President and Executive Chairman, Dr. Anil R. Diwan, participated in the Alliance Global Partners Healthcare Companies Showcase on May 20, 2026, in a fireside chat with A.G.P. equity research analyst Dr. James Molloy.

During the discussion, Dr. Diwan described two antiviral drug candidates developed during COVID-19: NV-387, a broad-spectrum antiviral now entering a Phase II clinical trial against Mpox in the Democratic Republic of Congo, and a backup candidate where remdesivir is encapsulated within NV-387 nanoviricide micelles as an oral formulation.

He explained that remdesivir has prior Ebola clinical trial and safety data, that NV-387 encapsulation is designed to protect remdesivir from rapid metabolism based on animal studies and a peer‑reviewed PLOS One publication, and that the company maintains both NV-387 alone and NV-387 with remdesivir as candidates the company expects could address the current Ebola Bundibugyo strain in DRC, subject to public health authorities’ decisions.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Terms

broad-spectrum antiviral, Phase II clinical trial, nanoviricide micelles, monoclonal antibodies cocktail, +2 more

6 terms

broad-spectrum antiviral medical

"NV-387 is a broad-spectrum antiviral, now entering Phase II clinical trial"

A broad-spectrum antiviral is a drug that can combat multiple different viruses rather than targeting just one, acting like a multi-tool instead of a single screwdriver. For investors, these medicines matter because they can address larger markets and respond to unforeseen outbreaks, potentially reducing development risk and increasing commercial value compared with treatments that work only against a single virus.

Phase II clinical trial medical

"NV-387 is a broad-spectrum antiviral, now entering Phase II clinical trial against Mpox in DRC"

A Phase II clinical trial is a mid-stage study in humans that tests whether an experimental drug or treatment actually works and what dose is effective, typically involving dozens to a few hundred patients and often comparing outcomes to a placebo or standard care. For investors, Phase II results are a major inflection point: clear positive data can substantially increase the odds of later regulatory approval and company value, while negative or uncertain results raise development risk and can sharply reduce expectations—like a detailed test drive after basic safety checks.

nanoviricide micelles medical

"We therefore developed an oral formulation of remdesivir by encapsulating it inside the NV-387 nanoviricide micelles"

monoclonal antibodies cocktail medical

"one was a Regeneron Monoclonal antibodies cocktail, and the other was an antibody isolated"

Bundibugyo strain medical

"both of which are expected to be effective against the current Ebola virus Bundibugyo strain in DRC"

peer-reviewed paper other

"We have in fact published a peer-reviewed paper in PLOS one on these studies"

Understanding 8-K Material Events →

05/21/2026 - 06:01 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 20, 2026

NANOVIRICIDES, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-36081	76-0674577
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1 Controls Drive Shelton, Connecticut		06484
(Address of Principal Executive Offices)		(Zip Code)

(203) 937-6137

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		NNVC		NYSE-American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01

Regulation FD Disclosure.

NanoViricides, Inc. (the “Company”) participated in the Alliance Global Partners (AGP) Healthcare Companies Showcase held on May 20, 2026. Dr. Anil R. Diwan, PhD, the Company’s President and Executive Chairman, participated as a panelist in a “fireside chat” interview with Dr. James Molloy, Managing Director, Equity Research, A.G.P. Dr. Molloy asked Dr. Diwan a question regarding whether the Company’s drug candidates could help in the current Ebolavirus epidemic in progress in Democratic Republic of Congo (DRC). Dr. Diwan responded as follows:

“During COVID-19, NanoViricides had developed two drug candidates, the first one, NV-387, and a back-up candidate, NV-387 encapsulating Remdesivir. NV-387 is a broad-spectrum antiviral, now entering Phase II clinical trial against Mpox in DRC. Remdesivir had gone into a clinical trial against Ebola already. In that clinical trial, two other antibodies were found to be superior to it and were approved for EBOV Zaire, one was a Regeneron Monoclonal antibodies cocktail, and the other was an antibody isolated and developed from an EBOV-Zaire survivor. Neither of these are responsive for the new Bundibugyo strain in DRC. Efficacy of remdesivir against Ebola in this clinical trial was not established, but safety and tolerability in humans was. That is the basis on which remdesivir entered the very first clinical trials and became the first approved drug to treat COVID-19 patients. Remdesivir was earlier found to be active against Ebola infection in animal models prior to these clinical trials. The problem was that remdesivir metabolizes readily in the bloodstream, limiting its efficacy in humans. Also, remdesivir is an infusion. We therefore developed an oral formulation of remdesivir by encapsulating it inside the NV-387 nanoviricide micelles, and showed that it was active in animal models of COVID. We have also demonstrated that this encapsulation protects remdesivir against bodily metabolism and improves its lifetime and thus its effect. We have in fact published a peer-reviewed paper in PLOS one on these studies. Because NV-387 by itself was highly effective as a broad-spectrum antiviral, we have continued clinical regulatory development of NV-387 by itself. And we keep NV-387 with Remdesivir encapsulated as the back-up candidate. So, to answer your question, yes, we have two candidates, NV-387 itself and NV-387 with Remdesivir encapsulated, both of which are expected to be effective against the current Ebola virus Bundibugyo strain in DRC. In addition, we do have a clinical site in DRC for treatment of Mpox patients. It depends upon the public health responders in DRC how to proceed.”

Some of the above information was previously undisclosed information that could be deduced by persons familiar with the Company based on the Company’s press release dated May 18, 2026, and the Company’s prior work that included Ebola viruses.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NanoViricides, Inc.

Date: May 21, 2026	By:	/s/ Anil Diwan
	Name:	Anil Diwan
	Title:	President, Chairman, Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did NanoViricides (NNVC) disclose about its participation in the AGP Healthcare Showcase?

NanoViricides disclosed that President and Executive Chairman Dr. Anil R. Diwan took part in a fireside chat at the Alliance Global Partners Healthcare Companies Showcase on May 20, 2026. He discussed the company’s antiviral pipeline, including NV-387 and an NV-387 formulation encapsulating remdesivir.

What is NanoViricides’ NV-387 drug candidate as described in this 8-K?

NV-387 is described as a broad-spectrum antiviral drug candidate now entering a Phase II clinical trial against Mpox in the Democratic Republic of Congo. The company has advanced NV-387 alone through clinical regulatory development based on its preclinical antiviral activity and existing development program.

How does NanoViricides (NNVC) use remdesivir in its backup candidate?

NanoViricides developed a backup candidate by encapsulating remdesivir inside NV-387 nanoviricide micelles to create an oral formulation. The company states this encapsulation aims to protect remdesivir from rapid metabolism and has shown activity in COVID animal models, supported by a peer-reviewed PLOS One publication.

What did NanoViricides say about potential treatment of the Ebola Bundibugyo strain?

Dr. Diwan stated the company has two candidates, NV-387 alone and NV-387 with encapsulated remdesivir, which the company expects could be effective against the current Ebola Bundibugyo strain in DRC. Any use would depend on decisions by public health responders in the Democratic Republic of Congo.

What additional disclosure did NanoViricides (NNVC) make about previously undisclosed information?

NanoViricides indicated that some information discussed in the fireside chat was previously undisclosed but could be deduced by knowledgeable observers from its May 18, 2026 press release and earlier Ebola-related work. The 8-K formally captures these comments for broader investor awareness and regulatory compliance.

Filing Exhibits & Attachments

3 documents